Industry
Biotechnology
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Loading...
Open
0.12
Mkt cap
14M
Volume
7.5M
High
0.15
P/E Ratio
-0.85
52-wk high
1.79
Low
0.12
Div yield
N/A
52-wk low
0.10
Portfolio Pulse from Benzinga Insights
September 30, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 12:10 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 10:08 am
Portfolio Pulse from Avi Kapoor
August 13, 2024 | 4:16 pm
Portfolio Pulse from Vandana Singh
August 13, 2024 | 3:18 pm
Portfolio Pulse from Avi Kapoor
August 13, 2024 | 1:54 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:38 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 12:06 pm
Portfolio Pulse from Avi Kapoor
July 18, 2024 | 10:00 am
Portfolio Pulse from Henry Khederian
July 17, 2024 | 7:20 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.